Affera

History

2022: Acquisition by Medtronic

plc Medtronic January 13, 2021 announced Zdrav.Expert the conclusion of a final agreement to acquire Affera Inc., a private medical technology company based in. Boston Affera develops and manufactures cardiac mapping and navigation systems, as well as catheter ablation technologies, hearts including a differentiated solution for focal ablation with a pulsed field, for the treatment of patients with cardiac arrhythmias (heart rhythm disorders), such as atrial fibrillation. Medtronic, having a minority portfolio, investments is a strategic investor in Affera and as of January 2022 owns a 3% stake in the company.

Medtronic is buying a Boston-based solution provider for the treatment of cardiac arrhythmia
Source photo: bostonrealestatetimes.com

In collaboration with physicians, researchers and scientists from around the world, Medtronic offers a wide range of medical technologies for interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. This acquisition will allow Medtronic to expand its portfolio of heart ablation products and support tools to help physicians provide medical care to an increased number of patients. Affera's full suite of solutions and technologies will complement Medtronic's existing portfolio for atrial and ventricular arrhythmias and enhance the company's ability to create simple, safe, and effective heart ablation solutions to improve patient outcomes.

Ablation and electrophysiological studies of the heart are a rapidly developing segment of cardiology. Affera's joining our company and our strong market position for cardiac catheter ablation solutions will expand our ability to provide innovative treatments and enter the market for electrophysiological research systems - mapping and navigation, noted Rebecca Seidel, president of Cardiac Ablation Solutions, which is part of Medtronic's cardiovascular portfolio.

Affera offers technologies that help physicians improve clinic performance, treatment outcomes, and ultimately optimize patient care, commented on Stacy Beske, Ph.D., vice president of strategy for Medtronic's Heart Ablation Solutions division.

The acquisition is expected to be completed in the first half of fiscal year 2023, subject to the terms of the transaction.

In the global market for cardiac electrophysiological research and catheter ablation systems with a turnover of US $8 billion, the prevalence of cardiac arrhythmias is growing rapidly, and with an increase in the number of patients with atrial fibrillation (AF), supratricular (NWT) and ventricular (GT) tachycardia, respectively, the need for treatment is growing. AF is one of the most common types of arrhythmias, worldwide this disease has been diagnosed in almost 60 million people. AF is a progressive disease, meaning that over time patients may experience more frequent and prolonged episodes of arrhythmias, and drug treatment and catheter ablation may become less effective. In addition, AF is associated with serious complications, including heart failure, stroke, and increased risk of death.

This is an important day for patients with atrial fibrillation and other arrhythmias. This transaction is consistent with our desire to develop new solutions to meet the rapidly growing needs for the treatment of cardiac arrhythmias. We are excited to focus on integrating our technology with Medtronic and are confident that together we will be able to increase patient access to heart ablation solutions, noted Doron Harlev (DoronHarlev), founder and CEO of Affera.